Eviplus

Eviplus is a fixed-dose combination pharmaceutical product developed by Rebrace Pharmaceuticals, containing 800 IU of Vitamin E (alpha-tocopherol) and Omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It is formulated as a soft gelatin capsule and is approved for the treatment of biopsy-proven non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and hypertriglyceridemia. The therapeutic rationale for Eviplus lies in the synergistic effects of its components: Vitamin E acts as a potent lipid-soluble antioxidant that reduces oxidative stress and prevents lipid peroxidation in the liver, while EPA and DHA modulate lipid metabolism by activating peroxisome proliferator-activated receptor alpha (PPAR-alpha) and inhibiting sterol regulatory element-binding protein 1 (SREBP-1c). These actions collectively work to reduce hepatic fat accumulation, inflammation, and serum triglyceride levels, addressing the underlying pathophysiology of metabolic liver diseases.

Brand names

Eviplus

Other names

EVIPLUS SOFT GELATINvitamin E + omega-3 fatty acidsvitamin E + EPA + DHA